Related Experiment Video
Updated: Aug 2, 2026
Mouse Models for Graft Arteriosclerosis
Published on: May 14, 2013
Cardiac allograft arteriopathy: an ischemic burden of a different sort
1Multi-Organ Transplant Center, Methodist Hospital, Houston, Texas.
Insights
Cardiac allograft arteriopathy is a distinct coronary artery disease affecting heart transplant recipients, often diagnosed late and impacting survival. Understanding its mechanisms is crucial for improved patient outcomes.
Area of Science:
- Cardiology
- Transplant Medicine
- Immunology
Background:
- Heart transplant recipients face a unique, accelerated coronary artery disease.
- Cardiac allograft arteriopathy (CAA) affects up to 90% of recipients within 5 years.
- CAA presents challenges in diagnosis due to limitations of noninvasive tests and angiography.
Purpose of the Study:
- To review the incidence, pathophysiology, prognosis, prevention, and treatment of cardiac allograft arteriopathy.
- To enhance understanding of this distinct form of coronary artery disease post-transplantation.
Main Methods:
- Review of existing literature on cardiac allograft arteriopathy.
- Analysis of diagnostic challenges and limitations.
- Exploration of etiological factors including immunological and atherosclerotic pathways.
Main Results:
- CAA is characterized by extensive, diffuse, and obliterative changes in distal coronary arteries.
- Endothelial injury is a likely trigger, with immunological mediation and atherosclerotic risk factors playing a role.
- Viral infections may also contribute to the development of CAA.
Conclusions:
- Cardiac allograft arteriopathy represents a significant threat to long-term survival in heart transplant recipients.
- Further research into prevention and treatment strategies is warranted.
- Accurate diagnosis and understanding of CAA's multifaceted etiology are essential.
Abstract:
As heart transplant recipients live longer, an accelerated and distinct form of coronary artery disease develops that adversely affects survival. Indeed, cardiac allograft arteriopathy may be detected in as many as 90% of heart transplant recipients after 5 years. The precise incidence is not easily determined because the disease can be difficult to recognize when noninvasive tests are used; even angiography has substantive limitations. The distinct characteristics of this type of coronary artery disease result in a different form of chronic ischemic syndrome. The angiographic hallmark of allograft arteriopathy is an extensive, diffuse, obliterative process that primarily involves distal, small, subendocardial arteries. Endothelial injury seems to trigger the disease process. The arteriopathy is likely immunologically mediated and promoted or exacerbated by traditional atherosclerotic disease risk factors. Viral infection may be involved as well. To gain a better understanding of allograft arteriopathy, it is worthwhile to review its incidence, pathophysiology, prognosis, prevention, and treatment.
